Heart failure & cardiomyopathies
Long-Term Efficacy of SGLT2 Inhibitors for Elderly Patients with Acute Decompensated Heart Failure: The OASIS-HF Study
Authors' conclusion
The SGLT2i are not only associated with the reduction of the composite events of HF rehospitalization or cardiovascular death and protect against worsening renal function but also with a decrease in long-term repeated HF rehospitalizations.
Study context
- Population
- Patients aged ≥75 years hospitalised for acute decompensated heart failure (HF)
- Participants
- 361 patients
- Exposure
- SGLT2i vs conventional medical therapy
- Outcome
- Composite of:
- HF rehospitalisation
- CV death
- Follow-up
- Average 24.9 months
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
P = 0.016
Observational data: associations, not effects.
Further findings
Annual HF rehospitalisations
P = 0.019
eGFR change over 1 year
- eGFR change significantly slower with SGLT2i vs conventional
- P = 0.025
- Printed as −3.55 ± 8.46 vs. −1.42 ± 7.28 mL/min/1.73 m² (group order as printed: SGLT2i vs conventional)
Original publication
Long-Term Efficacy of SGLT2 Inhibitors for Elderly Patients with Acute Decompensated Heart Failure: The OASIS-HF Study. ESC Heart Fail. Published 28 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →